CA2264748A1 - Le muc-1, agent therapeutique immunosuppresseur traitant les etats inflammatoires et auto-immunitaires - Google Patents

Le muc-1, agent therapeutique immunosuppresseur traitant les etats inflammatoires et auto-immunitaires Download PDF

Info

Publication number
CA2264748A1
CA2264748A1 CA002264748A CA2264748A CA2264748A1 CA 2264748 A1 CA2264748 A1 CA 2264748A1 CA 002264748 A CA002264748 A CA 002264748A CA 2264748 A CA2264748 A CA 2264748A CA 2264748 A1 CA2264748 A1 CA 2264748A1
Authority
CA
Canada
Prior art keywords
muc
derivative
mucâ
repeats
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002264748A
Other languages
English (en)
Inventor
Lyle H. Regimbald
B. Michael Longenecker
Judith C. Hugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncothyreon Canada Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2264748A1 publication Critical patent/CA2264748A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

L'invention porte sur de nouveaux modes de traitement et de nouvelles préparations pharmaceutiques à base de mucine MUC-1 et de ses dérivés. Les dérivés préférés comportent de multiples unités répétées en tandem de la séquence coeur du MUC-1. La figure montre que de faibles taux sériques de MUC-1 sont en relation avec une survie plus longue. Les préparations pharmaceutiques et procédés de l'invention sont particulièrement intéressants pour traiter les troubles de nature auto-immunitaire et inflammatoires, le rejet des greffes et les problèmes greffon/organisme récepteur.
CA002264748A 1996-09-10 1997-09-10 Le muc-1, agent therapeutique immunosuppresseur traitant les etats inflammatoires et auto-immunitaires Abandoned CA2264748A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2571896P 1996-09-10 1996-09-10
US60/025,718 1996-09-10
PCT/US1997/015928 WO1998010783A1 (fr) 1996-09-10 1997-09-10 Le muc-1, agent therapeutique immunosuppresseur traitant les etats inflammatoires et auto-immunitaires

Publications (1)

Publication Number Publication Date
CA2264748A1 true CA2264748A1 (fr) 1998-03-19

Family

ID=21827678

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002264748A Abandoned CA2264748A1 (fr) 1996-09-10 1997-09-10 Le muc-1, agent therapeutique immunosuppresseur traitant les etats inflammatoires et auto-immunitaires

Country Status (5)

Country Link
EP (1) EP0925071A4 (fr)
JP (1) JP2001501599A (fr)
AU (1) AU741258B2 (fr)
CA (1) CA2264748A1 (fr)
WO (1) WO1998010783A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2269349A1 (fr) * 1996-10-25 1998-04-30 Dana-Farber Cancer Institute, Inc. Immunomodulation induite par la mucine
AU2354700A (en) * 1998-12-11 2000-06-26 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
DE10056136A1 (de) * 2000-11-07 2002-05-16 Nemod New Modalities Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
WO2002062319A2 (fr) * 2001-01-19 2002-08-15 Corixa Corporation Administration sous forme de microspheres de peptides de mucine
SI1529060T1 (sl) 2002-07-22 2015-01-30 Glycotope Gmbh Postopek za proizvodnjo imunostimulacijskih mucinov (MUCI)
WO2010087521A1 (fr) 2009-01-29 2010-08-05 独立行政法人理化学研究所 Préparation combinée pour traiter les maladies articulaires

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
CA2269349A1 (fr) * 1996-10-25 1998-04-30 Dana-Farber Cancer Institute, Inc. Immunomodulation induite par la mucine

Also Published As

Publication number Publication date
AU741258B2 (en) 2001-11-29
JP2001501599A (ja) 2001-02-06
WO1998010783A1 (fr) 1998-03-19
AU4261397A (en) 1998-04-02
EP0925071A1 (fr) 1999-06-30
EP0925071A4 (fr) 2000-09-13

Similar Documents

Publication Publication Date Title
Hall et al. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action.
Munn et al. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma
Kamada et al. Reversal of transplantation immunity by liver grafting
Bierer et al. Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor.
Cavender et al. Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers.
Gajate et al. Lipid raft-mediated Fas/CD95 apoptotic signaling in leukemic cells and normal leukocytes and therapeutic implications
Liversidge et al. Interactions between lymphocytes and cells of the blood-retina barrier: mechanisms of T lymphocyte adhesion to human retinal capillary endothelial cells and retinal pigment epithelial cells in vitro.
Briscoe et al. Human endothelial cell costimulation of T cell IFN-gamma production.
JPH05504554A (ja) 免疫強化を促進するための方法と組成物
JP3345419B2 (ja) Ｃｄ８結合ドメイン・ペプチド
JPH03503887A (ja) 自己免疫疾患に対する抗ｔ細胞イムノトキシンの治療的使用
DE69333760T2 (de) Evaluierung von patienten mit progressiver immunosuppression
DE69529515T2 (de) Die regulation der aktivität zytotoxischer t-zelllymphozyten mit peptiden der mhc-klasse i
Wang et al. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404)
CA2264748A1 (fr) Le muc-1, agent therapeutique immunosuppresseur traitant les etats inflammatoires et auto-immunitaires
Wright et al. Allograft tolerance: presumptive evidence that serum factors from tolerant animals that block lymphocyte-mediated immunity in vitro are soluble antigen-antibody complexes
PRIESTLEY et al. A detailed analysis of the potential of water-soluble classical class I MHC molecules for the suppression of kidney allograft rejection and in vitro cytotoxic T cell responses
Kearney et al. Cellular basis for the immune response to methylcholanthrene‐induced tumors in mice. Heterogeneity of effector cells
Zhu et al. The B cell repertoire in experimental allergic neuritis involves multiple myelin proteins and GM1
Gallinger et al. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice
US20020044943A1 (en) MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
Aiello et al. A role for cytokines in antigen presentation: IL-1 and IL-4 induce accessory functions of antigen-presenting cells.
JPH07507541A (ja) 糖尿病の治療方法
EP1027373B1 (fr) Derives de muc-1 et leur utilisation pour traiter l'immunodepression induite par la mucine muc-1 et associee au cancer
Tovey et al. Role of the type I interferons in allograft rejection

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead